These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 10588978)

  • 21. Pharmacokinetics of chlorofluorocarbon and hydrofluoroalkane metered-dose inhaler formulations of beclomethasone dipropionate.
    Lipworth BJ; Jackson CM
    Br J Clin Pharmacol; 1999 Dec; 48(6):866-8. PubMed ID: 10594492
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetic and pharmacodynamic comparison of hydrofluoroalkane and chlorofluorocarbon formulations of budesonide.
    Clearie KL; Williamson PA; Meldrum K; Gillen M; Carlsson LG; Carlholm M; Ekelund J; Lipworth BJ
    Br J Clin Pharmacol; 2011 Apr; 71(4):504-13. PubMed ID: 21395643
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reformulation of Stmerin(®) D CFC formulation using HFA propellants.
    Murata S; Izumi T; Ito H
    Pharm Dev Technol; 2013; 18(6):1314-8. PubMed ID: 22519407
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Use of hydrofluoroalkane propellant delivery system for inhaled albuterol in patients receiving asthma medications.
    Boccuzzi SJ; Wogen J; Roehm JB
    Clin Ther; 2000 Feb; 22(2):237-47. PubMed ID: 10743983
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A randomized, double-blind, double-dummy, single-dose, efficacy crossover trial comparing formoterol-HFA (pMDI) versus formoterol-DPI (Aerolizer) and placebo (pMDI or Aerolizer) in asthmatic patients.
    Bousquet J; Huchon G; Leclerc V; Vicaut E; Lefrançois G
    Respiration; 2005; 72 Suppl 1():6-12. PubMed ID: 15915007
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Computational analyses of a pressurized metered dose inhaler and a new drug-aerosol targeting methodology.
    Kleinstreuer C; Shi H; Zhang Z
    J Aerosol Med; 2007; 20(3):294-309. PubMed ID: 17894536
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Moisture uptake and its influence on pressurized metered-dose inhalers.
    Williams RO; Hu C
    Pharm Dev Technol; 2000; 5(2):153-62. PubMed ID: 10810745
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Systemic exposure to fluticasone propionate administered via metered-dose inhaler containing chlorofluorocarbon or hydrofluoroalkane propellant.
    Mackie AE; McDowall JE; Ventresca P; Bye A; Falcoz C; Daley-Yates PT
    Clin Pharmacokinet; 2000; 39 Suppl 1():17-22. PubMed ID: 11140429
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Drug-surfactant-propellant interactions in HFA-formulations.
    Vervaet C; Byron PR
    Int J Pharm; 1999 Sep; 186(1):13-30. PubMed ID: 10469920
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The influence of initial atomized droplet size on residual particle size from pressurized metered dose inhalers.
    Sheth P; Stein SW; Myrdal PB
    Int J Pharm; 2013 Oct; 455(1-2):57-65. PubMed ID: 23911912
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The rejuvenated pressurised metered dose inhaler.
    Bell J; Newman S
    Expert Opin Drug Deliv; 2007 May; 4(3):215-34. PubMed ID: 17489650
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The ester group: how hydrofluoroalkane-philic is it?
    Peguin RP; Wu L; da Rocha SR
    Langmuir; 2007 Jul; 23(16):8291-4. PubMed ID: 17602576
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The technical transition to CFC-free inhalers.
    Tansey I
    Br J Clin Pract Suppl; 1997 May; 89():22-7. PubMed ID: 9519509
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Issues surrounding MDI formulation development with non-CFC propellants.
    Kontny MJ; Destefano G; Jager PD; McNamara DP; Turi JS; Van Campen L
    J Aerosol Med; 1991; 4(3):181-7. PubMed ID: 10147677
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Reverse water-in-fluorocarbon emulsions for use in pressurized metered-dose inhalers containing hydrofluoroalkane propellants.
    Butz N; Porté C; Courrier H; Krafft MP; Vandamme TF
    Int J Pharm; 2002 May; 238(1-2):257-69. PubMed ID: 11996829
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effects of HFA- and CFC-beclomethasone dipropionate on the bronchial response to methacholine (MCh) in mild asthma.
    Micheletto C; Guerriero M; Tognella S; Dal Negro RW
    Respir Med; 2005 Jul; 99(7):850-5. PubMed ID: 15939246
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Double-blind, double-dummy, multinational, multicenter, parallel-group design clinical trial of clinical non-inferiority of formoterol 12 microg/unit dose in a b.i.d. regimen administered via an HFA-propellant-pMDI or a dry powder inhaler in a 12-week treatment period of moderate to severe stable persistent asthma in adult patients.
    Dusser D; Vicaut E; Lefrançois G;
    Respiration; 2005; 72 Suppl 1():20-7. PubMed ID: 15915009
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Changes in metered dose inhaler propellants].
    Chinet T
    Rev Mal Respir; 2000 Feb; 17(1):15-20. PubMed ID: 10756552
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Review of Methods for Evaluating Particle Stability in Suspension Based Pressurized Metered Dose Inhalers.
    D'Sa D; Chan HK
    Curr Pharm Des; 2015; 21(27):3955-65. PubMed ID: 26290200
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical efficacy and safety of fluticasone propionate 250 microg twice daily administered via a HFA 134a pressurized metered dose inhaler to patients with mild to moderate asthma. French study group.
    Tonnel AB; Bons J; Legendre M; Prud'Homme A; Bugnas B; Evano-Celli I; Stuart AM
    Respir Med; 2000 Jun; 94 Suppl B():S29-34. PubMed ID: 10919683
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.